Indivior Pharmaceuticals, Inc. INDV 深 沪
交易中 05-11 10:33:07 美东时间
39.55
+0.060
+0.15%
华盛通- 最 高41.00
- 今 开39.22
- 成交量 15.06万股
- 最 低 39.0101
- 昨 收 39.49
- 总市值 0
- 52周最高 41.00
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 11.065
- 委 比 83.78%
- 总股本 --
- 历史最高 41.00
- 量 比 0.51
- 振 幅 5.04%
- 历史最低 1.10
- 每 手 1
- 风险率 8.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For April 30, 2026
Companies Reporting Before The Bell • Sonic Automotive (NYSE:SAH) is projected ...
04-30 19:11
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
Top 3 Health Care Stocks That May Explode This Month
The most oversold stocks in the health care sector presents an opportunity to b...
2024-09-23 19:13
Piper Sandler Reiterates Overweight on Indivior, Maintains $22 Price Target
Piper Sandler analyst David Amsellem reiterates Indivior (NASDAQ:INDV) with a Overweight and maintains $22 price target.
2024-09-13 23:35
French Biotech Candidate For Cannabis Use Disorder Fails Phase 2B Clinical Trial, Indivior Will Not Exercise Option
French biotechnology company specializing in the treatment of brain disorders A...
2024-09-05 10:27
French Biotech Candidate For Cannabis Use Disorder Fails Phase 2B Clinical Trial, Indivior Will Not Exercise Option
French biotechnology company specializing in the treatment of brain disorders Aelis Farma reported Wednesday the results from its clinical Phase 2B trial with AEF0117, evaluating the efficacy and safety in treatment-seeking participants with moderate to severe cannabis use disorder (CUD). The study ...
2024-09-05 10:27
Indivior Shares Update On Aelis Farma's Phase 2B Study With AEF0117 In Participants With Cannabis Use Disorder
Primary and Secondary End Points of the Study were Not Met Indivior Does Not Currently Expect to Exercise AEF0117 Option
2024-09-04 14:35
Health And Human Services Dept Orders OPVEE Nasal Spray For Emergency Fentanyl Overdose Response
Indivior PLC (NASDAQ:INDV) confirmed the first order of the OPVEE (nalmefene) nasal spray from the Biomedical Advanced Research and Development Authority (BARDA), which is the Department of Health and Human Services’ office responsible for procurement and development of medical countermeasures. The ...
2024-08-27 21:02
Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder
Tuesday, Addex Therapeutics Ltd (NASDAQ:ADXN) stock is trading higher with a session volume of 3.79 million versus the average volume of 4.16K as per data from Benzinga Pro. Addex Therapeutics and Indivior PLC (NASDAQ:INDV) announced that they have selected clinical candidates from their GABAB-posit...
2024-08-27 20:48
Indivior Says BARDA Makes 1st Order of Opioid Overdose Reversal Nasal Spray
11:14 AM EDT, 08/26/2024 (MT Newswires) -- Indivior (INDV) said Monday that the Biomedical Advanced Research and Development Authority or BARDA has made its first order of Opvee, a nalmefene opioid overdose reversal nasal spray. The company said $8.7 million in Project BioShield designated funding f...
2024-08-26 23:14
